NO983946L - Parapoxviruser inneholdende fremmed DNA, fremstilling og anvendelse derav i vaksiner - Google Patents

Parapoxviruser inneholdende fremmed DNA, fremstilling og anvendelse derav i vaksiner

Info

Publication number
NO983946L
NO983946L NO983946A NO983946A NO983946L NO 983946 L NO983946 L NO 983946L NO 983946 A NO983946 A NO 983946A NO 983946 A NO983946 A NO 983946A NO 983946 L NO983946 L NO 983946L
Authority
NO
Norway
Prior art keywords
vaccines
preparation
foreign dna
containing foreign
viruses containing
Prior art date
Application number
NO983946A
Other languages
English (en)
Norwegian (no)
Other versions
NO983946D0 (no
Inventor
Norbert Schmeer
Walter Strube
Ttner Mathias B
Hans-Joachim Rziha
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19639601A external-priority patent/DE19639601A1/de
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO983946D0 publication Critical patent/NO983946D0/no
Publication of NO983946L publication Critical patent/NO983946L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO983946A 1996-02-28 1998-08-27 Parapoxviruser inneholdende fremmed DNA, fremstilling og anvendelse derav i vaksiner NO983946L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19607458 1996-02-28
DE19639601A DE19639601A1 (de) 1996-02-28 1996-09-26 Parapockenviren, die Fremd-DNA enthalten, ihre Herstellung und ihre Verwendung in Impfstoffen
PCT/EP1997/000729 WO1997032029A1 (de) 1996-02-28 1997-02-17 Parapockenviren, die fremd-dna enthalten, ihre herstellung und ihre verwendung in impfstoffen

Publications (2)

Publication Number Publication Date
NO983946D0 NO983946D0 (no) 1998-08-27
NO983946L true NO983946L (no) 1998-10-22

Family

ID=26023280

Family Applications (1)

Application Number Title Priority Date Filing Date
NO983946A NO983946L (no) 1996-02-28 1998-08-27 Parapoxviruser inneholdende fremmed DNA, fremstilling og anvendelse derav i vaksiner

Country Status (19)

Country Link
US (1) US6365393B1 (sk)
EP (1) EP0886679B1 (sk)
JP (1) JP2000507092A (sk)
CN (1) CN1217027A (sk)
AT (1) ATE364090T1 (sk)
AU (1) AU718141B2 (sk)
BR (1) BR9707785A (sk)
CA (1) CA2247336C (sk)
DE (1) DE59712852D1 (sk)
DK (1) DK0886679T3 (sk)
ES (1) ES2287949T3 (sk)
HU (1) HUP9901035A3 (sk)
IL (1) IL125797A0 (sk)
NO (1) NO983946L (sk)
NZ (1) NZ331556A (sk)
PL (1) PL190401B1 (sk)
SK (1) SK120098A3 (sk)
TR (1) TR199801702T2 (sk)
WO (1) WO1997032029A1 (sk)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126349A0 (en) * 1996-03-29 1999-05-09 Univ Otago Parapoxvirus vectors
AU758353B2 (en) * 1998-03-17 2003-03-20 Genentech Inc. Polypeptides homologous to VEGF and BMP1
JP2003517275A (ja) * 1998-11-02 2003-05-27 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 哺乳動物ｖｅｇｆレセプター−２に結合し、これを活性化するオルフウイルスｎｚ２由来の血管内皮細胞増殖因子様タンパク質
DE50109630D1 (de) * 2000-07-11 2006-06-01 Bayer Healthcare Ag Verwendung von stämmen des parapoxvirus ovis zur herstellung von antiviralen arzneimitteln und arzneimitteln gegen krebs
US6752995B2 (en) * 2002-04-15 2004-06-22 Board Of Regents, The University Of Texas System Nucleic acid and polypeptide sequences useful as adjuvants
EP1499355A4 (en) 2001-12-07 2005-10-05 Bayer Pharmaceuticals Corp USE OF PARAPOX B2L PROTEIN FOR THE TREATMENT OF CANCER AND THE MODIFICATION OF IMMUNE RESPONSES
EP1765370B1 (en) * 2004-07-13 2009-09-09 AiCuris GmbH & Co. KG Parapoxviruses in combination with other antiviral agents for the treatment of hiv/aids
KR20130058706A (ko) * 2010-04-29 2013-06-04 림사 아르쯔나이미텔 아게 토끼 출혈병 바이러스의 ｖｐ６０ 주요 캡시드 단백질을 발현하는 파라폭스바이러스
NZ603431A (en) * 2010-05-21 2014-06-27 Zoetis Llc Parapoxvirus vectors containing rabies virus antigen
JP2013537409A (ja) 2010-07-20 2013-10-03 ゾエティス・エルエルシー パラポックスウイルスベクター
MX2015000789A (es) 2012-07-19 2015-05-07 Zoetis Llc Composiciones de virus de la gripe bovina.
AU2013295770A1 (en) 2012-07-27 2015-01-29 Zoetis Services Llc Tick toxin compositions
DE102015111756A1 (de) * 2015-07-20 2017-01-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Rekombinanter Orf-Virus-Vektor
CN108135989B (zh) 2015-08-14 2022-08-09 硕腾服务有限责任公司 牛支原体组合物
BR112018069371A2 (pt) 2016-03-21 2019-01-22 South Dakota Board Of Regents construção de ácido nucleico, vetor, vacina ou composição imunogênica, método de entrega de uma vacina, método de produção de uma construção de ácido nucleico e método para conferir imunidade contra um antígeno
MX2020009262A (es) 2018-03-07 2021-01-08 Transgene Vectores de parapoxvirus.
WO2024062098A1 (en) 2022-09-23 2024-03-28 Transgene Recombinant pseudocowpox virus encoding an interleukin-12

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2188447C (en) * 1994-04-29 2002-10-22 Falko-Gunter Falkner Recombinant poxviruses with foreign polynucleotides in essential regions

Also Published As

Publication number Publication date
CA2247336C (en) 2008-06-17
JP2000507092A (ja) 2000-06-13
HUP9901035A3 (en) 2001-01-29
AU1725797A (en) 1997-09-16
NO983946D0 (no) 1998-08-27
DE59712852D1 (de) 2007-07-19
ATE364090T1 (de) 2007-06-15
BR9707785A (pt) 1999-07-27
HUP9901035A2 (hu) 1999-07-28
PL328870A1 (en) 1999-03-01
DK0886679T3 (da) 2007-09-24
US6365393B1 (en) 2002-04-02
WO1997032029A1 (de) 1997-09-04
IL125797A0 (en) 1999-04-11
ES2287949T3 (es) 2007-12-16
PL190401B1 (pl) 2005-12-30
TR199801702T2 (xx) 1998-12-21
SK120098A3 (en) 1999-03-12
NZ331556A (en) 2000-05-26
CN1217027A (zh) 1999-05-19
EP0886679B1 (de) 2007-06-06
CA2247336A1 (en) 1997-09-04
AU718141B2 (en) 2000-04-06
EP0886679A1 (de) 1998-12-30

Similar Documents

Publication Publication Date Title
NO983946L (no) Parapoxviruser inneholdende fremmed DNA, fremstilling og anvendelse derav i vaksiner
ATE404220T1 (de) Rekombinierte pockenvirus-tollwut zusammensetzung und kombinierte zusammensetzungen und deren verwendung
DE69830579D1 (de) Chimäre impfstoffe gegen flaviviren
MY150893A (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
DK1021547T3 (da) Vaccineformuleringer indeholdende papillomviruskapsomer og fremgangsmåder til anvendelse heraf
BRPI0309631A8 (pt) vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31' dos tipos de dengue 1,2,3 e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4
NO20013701L (no) HER-2/neu-fusjonsproteiner
BRPI9912663B8 (pt) vacina contra cáncer e polipeptìdeo.
ATE328068T1 (de) Papillomavirus vakzine
ATE286067T1 (de) Hcv hüllproteine partikel : verwendung für therapeutische impfung
YU36698A (sh) Parapoks-virusi koji sadrže stranu dnk, njihovo dobijanje i njihova primena u vakcinama
EP0868522A4 (en) RECOMBINANT POX VIRUS OF INFECTIOUS PERITONITIS OF THE CAT, COMPOSITIONS THEREOF AND METHODS FOR THE PRODUCTION AND USE
ATE346931T1 (de) Clostridium perfringens impfstoff
ATE424217T1 (de) Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen
HUP0001991A2 (hu) Varicella Zoster vírus 63-as géntermékkel szembeni vakcinák
ATE381351T1 (de) Anwendung des herpes simplex virus glykoproteins- d zur unterdrückung von immunantworten
NZ511168A (en) Recombinant CELO virus and CELO virus DNA
BR9915970A (pt) Vìrus recombinante expressando dna exógenocodificando cd80 felino, ctla-4 felino ou cd86 felinoe usos do mesmo
NZ330913A (en) Antigens for preventing and reducing parasite infection and disease
ATE132527T1 (de) Nicht-zurückmutierende rna-viren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application